HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Atsushi Kasai Selected Research
Atsushi Kasai Research Topics
Disease
6
Schizophrenia (Dementia Praecox)
10/2021 - 12/2010
4
Infections
10/2020 - 12/2015
3
Autistic Disorder (Autism)
11/2019 - 01/2016
3
Mental Disorders (Mental Disorder)
01/2019 - 01/2014
3
Neoplasms (Cancer)
05/2015 - 02/2014
2
Autism Spectrum Disorder
01/2021 - 01/2020
2
Parkinsonian Disorders (Parkinsonism)
01/2021 - 01/2018
2
Retinal Diseases
01/2011 - 11/2010
2
Diabetic Retinopathy (Retinopathy, Diabetic)
01/2011 - 11/2010
2
Hypoxia (Hypoxemia)
01/2011 - 11/2010
1
Movement Disorders (Movement Disorder)
01/2021
1
Catalepsy
01/2021
1
Anhedonia
01/2020
1
Intellectual Disability (Idiocy)
01/2020
1
Neurodevelopmental Disorders
01/2020
1
Necrosis
01/2019
1
Nervous System Diseases (Neurological Disorders)
01/2019
1
Treatment-Resistant Schizophrenia
01/2017
1
AIDS-Related Complex (ARC)
11/2016
1
Cognitive Dysfunction
11/2016
1
Neuroblastoma
03/2016
1
Fibrosis (Cirrhosis)
02/2016
1
Infarction (Infarctions)
02/2016
1
Heart Failure
02/2016
1
Hyperinsulinism (Hyperinsulinemia)
07/2015
1
Diabetes Mellitus
07/2015
1
Hyperplasia
07/2015
1
Primitive Neuroectodermal Tumors (PNET)
01/2015
1
Anorexia
02/2014
1
Hypothermia
01/2014
1
Pathologic Neovascularization
07/2013
1
Choroidal Neovascularization
06/2013
1
Aneurysm (Aneurysms)
01/2011
1
Eye Diseases (Eye Disease)
01/2011
1
Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
01/2011
1
Retinal Neovascularization
11/2010
1
Virus Diseases (Viral Diseases)
11/2007
1
Urinary Tract Infections (Urinary Tract Infection)
03/2007
Drug/Important Bio-Agent (IBA)
5
Apelin
IBA
07/2013 - 11/2010
3
Pharmaceutical Preparations
IBA
01/2021 - 01/2015
3
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
IBA
01/2019 - 01/2014
3
Proteins (Proteins, Gene)
FDA Link
01/2018 - 11/2007
3
N-Methyl-D-Aspartate Receptors (NMDA Receptors)
IBA
11/2016 - 12/2010
3
Oxygen (Dioxygen)
IBA
07/2013 - 11/2010
3
Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
IBA
01/2011 - 11/2010
2
RNA (Ribonucleic Acid)
IBA
09/2020 - 12/2015
2
Antipsychotic Agents (Antipsychotics)
IBA
11/2019 - 01/2017
2
Dizocilpine Maleate (Dizocilpine)
IBA
11/2016 - 11/2016
2
Small Interfering RNA (siRNA)
IBA
03/2016 - 07/2013
2
ramatroban
IBA
05/2015 - 02/2014
2
Corticosterone
IBA
05/2015 - 01/2014
2
Lipopolysaccharides
IBA
05/2015 - 02/2014
2
Retinaldehyde (Retinal)
IBA
01/2011 - 11/2010
1
Dopamine D2 Receptors (Dopamine D2 Receptor)
IBA
10/2021
1
Dopamine (Intropin)
FDA Link
Generic
01/2021
1
Oxytocin (Pitocin)
FDA Link
Generic
01/2021
1
Dopamine Receptors (Dopamine Receptor)
IBA
01/2021
1
Viral RNA
IBA
10/2020
1
DNA Transposable Elements (Element, IS)
IBA
01/2020
1
6-hydroxynorketamine
IBA
01/2020
1
Protein Kinase D2
IBA
11/2019
1
Valproic Acid (Depakote)
FDA Link
Generic
01/2019
1
Reactive Oxygen Species (Oxygen Radicals)
IBA
01/2019
1
Superoxide Dismutase-1
IBA
01/2019
1
Neuropeptides
IBA
01/2019
1
Copper
IBA
01/2019
1
Clozapine (Clozaril)
FDA Link
Generic
01/2017
1
Indicators and Reagents (Reagents)
IBA
11/2016
1
N-Methylaspartate (NMDA)
IBA
11/2016
1
Prostaglandin D2
IBA
11/2016
1
Enzymes
IBA
11/2016
1
Cyclooxygenase 1
IBA
11/2016
1
Leucine (L-Leucine)
FDA Link
02/2016
1
Biomarkers (Surrogate Marker)
IBA
02/2016
1
DNA (Deoxyribonucleic Acid)
IBA
01/2016
1
Nucleotides
IBA
12/2015
1
Glucose (Dextrose)
FDA Link
Generic
07/2015
1
prostaglandin D2 receptor
IBA
02/2014
1
Endothelial Growth Factors
IBA
07/2013
1
G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
IBA
01/2011
1
Antibodies
IBA
01/2011
1
Ligands
IBA
01/2011
1
Neuregulin-1 (Neuregulin 1)
IBA
12/2010
1
Messenger RNA (mRNA)
IBA
11/2010
1
Erythropoietin
FDA Link
11/2010
1
Quercetin
IBA
11/2007
1
kaempferol
IBA
11/2007
1
Acetyltransferases
IBA
03/2007
Therapy/Procedure
2
Transplantation
02/2016 - 01/2015
2
Therapeutics
01/2011 - 11/2010
1
Bone Marrow Transplantation (Transplantation, Bone Marrow)
02/2016
1
Lasers (Laser)
06/2013
1
Catheters
03/2007